A part of Watch Medier Global Clinical Lead, Clinical Development, Migraine & Pain Pharmacokineticist, PK/PD Modelling & Simulation Clinical Supply Manager Medical Writer responsible for Clinical Disclosure Director, Drug Safety Operations Senior Safety Manager You need to be a subscriber to read the rest of the article
GH reports research grants from the Netherlands Organization for Scientific Research (vidi 016.156.445), CardioVascular Research Initiative, European Union and the Klinkerpad fonds, institutional research support from Aegerion, Amgen, AstraZeneca, Eli Lilly, Genzyme, Ionis, Kowa, Pfizer, Regeneron, Roche, Sanofi, and The Medicines Company
Several considerations are worth noting: Metabolic overlap: Both NAD+ precursors and retatrutide influence metabolic pathways
A plausible reading is that within the next three to five years, one to three of these programs will advance to IND, and one or more will be candidates for licensing by Novo, Lilly, Pfizer, Roche, or a mid-cap U.S
The thermogenic effect becomes noticeable
Data are presented as a percentage of MTP protein expression versus the loading control GAPDH ( n = 3)
